AU2005335298C1 - N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof - Google Patents

N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof Download PDF

Info

Publication number
AU2005335298C1
AU2005335298C1 AU2005335298A AU2005335298A AU2005335298C1 AU 2005335298 C1 AU2005335298 C1 AU 2005335298C1 AU 2005335298 A AU2005335298 A AU 2005335298A AU 2005335298 A AU2005335298 A AU 2005335298A AU 2005335298 C1 AU2005335298 C1 AU 2005335298C1
Authority
AU
Australia
Prior art keywords
preparation
pyrimidin
methyl
cancer
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2005335298A
Other languages
English (en)
Other versions
AU2005335298B2 (en
AU2005335298A1 (en
Inventor
Dae-Jin Cho
Byoung-Cheol Han
Dong-Yeon Kim
Hong-Youb Kim
Yong-Seok Kim
Gong-Yeal Lee
Sun-Ahe Lee
Seok-Hun Woo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Il Yang Pharmaceutical Co Ltd
Original Assignee
Il Yang Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il Yang Pharmaceutical Co Ltd filed Critical Il Yang Pharmaceutical Co Ltd
Publication of AU2005335298A1 publication Critical patent/AU2005335298A1/en
Publication of AU2005335298B2 publication Critical patent/AU2005335298B2/en
Application granted granted Critical
Publication of AU2005335298C1 publication Critical patent/AU2005335298C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Pyridine Compounds (AREA)
AU2005335298A 2005-08-05 2005-09-07 N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof Active AU2005335298C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020050071656A KR100674813B1 (ko) 2005-08-05 2005-08-05 N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
KR10-2005-0071656 2005-08-05
PCT/KR2005/002962 WO2007018325A1 (en) 2005-08-05 2005-09-07 N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof

Publications (3)

Publication Number Publication Date
AU2005335298A1 AU2005335298A1 (en) 2007-02-15
AU2005335298B2 AU2005335298B2 (en) 2010-05-27
AU2005335298C1 true AU2005335298C1 (en) 2010-11-25

Family

ID=37727490

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005335298A Active AU2005335298C1 (en) 2005-08-05 2005-09-07 N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof

Country Status (16)

Country Link
US (1) US7501424B2 (xx)
EP (1) EP1922309B1 (xx)
JP (1) JP5094721B2 (xx)
KR (1) KR100674813B1 (xx)
CN (1) CN101155786B (xx)
AU (1) AU2005335298C1 (xx)
CA (1) CA2617991C (xx)
DK (1) DK1922309T3 (xx)
EA (1) EA015103B1 (xx)
ES (1) ES2493627T3 (xx)
MX (1) MX2008001221A (xx)
NZ (1) NZ564908A (xx)
PL (1) PL1922309T3 (xx)
PT (1) PT1922309E (xx)
RS (1) RS53379B (xx)
WO (1) WO2007018325A1 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100654039B1 (ko) 2005-11-14 2006-12-05 에스케이 텔레콤주식회사 무선 인터넷에서 서비스 서버의 인증방법 및 이를 이용한결제방법
ES2633318T3 (es) 2006-10-23 2017-09-20 Cephalon, Inc. Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
KR20120049397A (ko) * 2006-11-03 2012-05-16 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
CN101687853A (zh) 2007-05-04 2010-03-31 Irm责任有限公司 作为c-kit和pdgfr激酶抑制剂的嘧啶衍生物和组合物
CA2686382C (en) * 2007-05-04 2013-09-17 Irm Llc Phenylaminopyrimidine derivatives and compositions thereof as c-kit and pdgfr kinase inhibitors
WO2008151183A1 (en) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
EA017392B1 (ru) 2007-08-22 2012-12-28 Айрм Ллк Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
KR20100021321A (ko) * 2008-08-14 2010-02-24 일양약품주식회사 Ν-페닐-2-피리미딘-아민 유도체의 제조방법
KR101251726B1 (ko) 2008-11-05 2013-04-05 테바 파마슈티컬 인더스트리즈 리미티드 닐로티닙 HCl 결정형
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
CN103003264B (zh) 2010-05-21 2014-08-06 切米利亚股份公司 嘧啶衍生物
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
KR101369584B1 (ko) 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
RU2486180C1 (ru) * 2011-11-02 2013-06-27 Общество с ограниченной ответственностью "ТехноХим" (ООО "ТехноХим") Способ получения 2-ариламино-4-гетарилпиримидинов
KR101956586B1 (ko) * 2012-03-27 2019-03-11 일양약품주식회사 약제학적 조성물 및 이의 제조방법
JP5910311B2 (ja) * 2012-05-23 2016-04-27 ニプロ株式会社 医薬錠剤およびその製造方法
CN104940748A (zh) * 2015-06-09 2015-09-30 林正兴 一种治疗胃癌的药物组合物
EP3609882B1 (en) 2017-03-17 2022-07-13 Cardio Therapeutics Pty Ltd Heterocyclic inhibitors of pcsk9
CN107056713A (zh) * 2017-05-18 2017-08-18 厦门大学 4‑((4‑取代芳基‑2‑嘧啶基)氨基)苯甲酰肼衍生物及其制备方法和应用
CN111039932B (zh) * 2019-12-13 2023-09-12 安徽峆一药业股份有限公司 一种拉多替尼的高收率合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011836A1 (en) * 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2004087699A2 (en) * 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
AU5127800A (en) * 1999-05-13 2000-12-05 Nutrasweet Company, The Use of additives to modify the taste characteristics of n-neohexyl-alpha-aspartyl-l-phenylalanine methyl ester
BR0014454A (pt) * 1999-10-04 2002-08-20 Composição edulcorante com um alto grau de edulcoração, edulcorante, alimento e bebida, ou um outro produto edulcorado, processos para conferir um sabor doce, e para corrigir um sabor, modificador de sabor, e, alimento e bebida, um medicamento etc. com sabor amargo aperfeiçoado
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
WO2002024681A2 (en) * 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
ATE339418T1 (de) * 2001-06-01 2006-10-15 Vertex Pharma Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
US7494997B2 (en) * 2002-06-28 2009-02-24 Nippon Shinyaku Co., Ltd. Amide derivative
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2004087698A2 (en) * 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
AU2003232650A1 (en) 2003-05-06 2004-11-26 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
JP2006527230A (ja) * 2003-06-13 2006-11-30 ノバルティス アクチエンゲゼルシャフト Rafキナーゼ阻害剤としての2−アミノピリミジン誘導体
PT1702917T (pt) * 2003-12-25 2017-11-14 Nippon Shinyaku Co Ltd Derivado de amida e medicamento
WO2005063720A1 (ja) * 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
JPWO2005113550A1 (ja) * 2004-05-20 2008-03-27 三菱ウェルファーマ株式会社 アミノピリミジン誘導体及びその医薬としての用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011836A1 (en) * 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2004087699A2 (en) * 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D3: MANLEY et aI., Bioorganic & Medicinal Chemistry Letters, 2003, Vo1.13, pp.1673-1677 *

Also Published As

Publication number Publication date
KR100674813B1 (ko) 2007-01-29
AU2005335298B2 (en) 2010-05-27
US7501424B2 (en) 2009-03-10
EA015103B1 (ru) 2011-06-30
AU2005335298A1 (en) 2007-02-15
DK1922309T3 (da) 2014-08-25
EP1922309A1 (en) 2008-05-21
CA2617991A1 (en) 2007-02-15
ES2493627T3 (es) 2014-09-12
JP5094721B2 (ja) 2012-12-12
CA2617991C (en) 2011-08-09
CN101155786A (zh) 2008-04-02
JP2009503060A (ja) 2009-01-29
CN101155786B (zh) 2012-08-29
MX2008001221A (es) 2009-02-24
EA200800516A1 (ru) 2008-08-29
PL1922309T3 (pl) 2014-11-28
EP1922309B1 (en) 2014-05-21
PT1922309E (pt) 2014-09-02
WO2007018325A1 (en) 2007-02-15
RS20080002A (xx) 2009-07-15
EP1922309A4 (en) 2009-10-14
NZ564908A (en) 2011-02-25
RS53379B (en) 2014-10-31
US20080096899A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
AU2005335298C1 (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
JP6506779B2 (ja) 医薬化合物
JP2019052181A (ja) Ezh2阻害のための塩酸塩形
US7595323B2 (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
WO2003011854A1 (en) Pyrazole-derived kinase inhibitors and uses thereof
CA2967737A1 (en) N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
CA2539297C (en) Substituted triazole derivatives as oxytocin antagonists
CA2889697A1 (en) Cannabinoid receptor mediating compounds
US9233969B2 (en) Therapeutic agent for cerebral infarction
WO2000043385A1 (fr) Composes heterocycliques et agents antitumoraux les comprenant en tant que principe actif
WO2003002540A1 (en) Cyclic diamine compound having five-membered cyclic group
JP2018522899A (ja) ベンジリデングアニジン誘導体と化学療法剤の併用による癌の治療方法
AU2006309576B2 (en) Ortho-substituted aniline derivative and antioxidant drug
JPH11171886A (ja) アミジンまたはグアニジンを側鎖にもつピロリルベンズイミダゾール誘導体
JP5872591B2 (ja) ピラゾール化合物
US20100063064A1 (en) Substituted Triazole Derivatives As Oxytocin Antagonists
RU2795572C2 (ru) Соединения и композиции для ингибирования ire1
JP3197495B2 (ja) ピロリルベンズイミダゾール誘導体
JPH04235983A (ja) 新規キノリン誘導体およびそれを有効成分として含有する制癌剤効果増強剤
TW200950782A (en) Therapeutic agent for cerebral infarction

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 JUL 2010.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 JUL 2010

FGA Letters patent sealed or granted (standard patent)